Inspire strikes settlement deal with SEC over eye drug

10/1/2008 | News & Observer (Raleigh, N.C.), The

Inspire Pharmaceuticals has reached a settlement agreement with the Securities and Exchange Commission, ending a formal investigation into the company's clinical studies for an experimental dry-eye medication, according to a regulatory filing. The SEC probe stemmed from allegations that Inspire omitted information and made false statements in its reports to investors.

View Full Article in:

News & Observer (Raleigh, N.C.), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT